Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.12890/2020_001790 http://scihub22266oqcxt.onion/10.12890/2020_001790 32665940!7350955!32665940     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+J+Case+Rep+Intern+Med 2020 ; 7 (7): 001790 Nephropedia Template TP {{tp|p=32665940|t=2020. Late Pulmonary Embolism after COVID-19 Pneumonia despite Adequate Rivaroxaban Treatment |pdf=|usr=}}{{32665940}} gab.com Text Late Pulmonary Embolism after COVID-19 Pneumonia despite Adequate Rivaroxaban Treatment JO: Eur J Case Rep Intern Med http://www.kidney.de/pget.php?&tw=1&pmid=32665940 #FOAvip INTRODUCTION: SARS-CoV-2 infection may predispose patients to thrombotic disease. Patients with COVID-19 pneumonia who are receiving non-vitamin K antagonists or direct oral anticoagulants for chronic disease are usually switched to heparin treatment during hospitalization. However, information about the most appropriate antithrombotic therapy after the acute infection phase is lacking. CASE DESCRIPTION: We report the case of a patient with chronic atrial fibrillation who was recently hospitalized for severe COVID-19 pneumonia. Four weeks after discharge he experienced an episode of an acute pulmonary embolism while on rivaroxaban therapy with adequate drug plasma levels, and in the absence of strong predisposing risk factors. CONCLUSION: This case highlights the risk of thrombotic complications after COVID-19 infection, raises some concern about their underlying mechanisms, and supports the use of effective anti-thrombotic therapy. LEARNING POINTS: COVID-19 infection is associated with frequent thrombotic events.A pro-coagulative status could be triggered by the persistent inflammatory phase of the infection despite anticoagulation.Adequate antithrombotic therapy is necessary for the prevention of acute and later thrombotic complications and needs close monitoring. Twit Text FOAVip Late Pulmonary Embolism after COVID-19 Pneumonia despite Adequate Rivaroxaban Treatment ????Eur J Case Rep Intern Med http://www.kidney.de/pget.php?&tw=1&pmid=32665940 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32665940 #FOAvip English Wikipedia <ref>{{Cite pmid|32665940}}</ref> Late Pulmonary Embolism after COVID-19 Pneumonia despite Adequate Rivaroxaban Treatment #MMPMID32665940 Di Tano G; Moschini L; Loffi M; Testa S; Danzi GB Eur J Case Rep Intern Med 2020[]; 7 (7): 001790 PMID32665940show ga INTRODUCTION: SARS-CoV-2 infection may predispose patients to thrombotic disease. Patients with COVID-19 pneumonia who are receiving non-vitamin K antagonists or direct oral anticoagulants for chronic disease are usually switched to heparin treatment during hospitalization. However, information about the most appropriate antithrombotic therapy after the acute infection phase is lacking. CASE DESCRIPTION: We report the case of a patient with chronic atrial fibrillation who was recently hospitalized for severe COVID-19 pneumonia. Four weeks after discharge he experienced an episode of an acute pulmonary embolism while on rivaroxaban therapy with adequate drug plasma levels, and in the absence of strong predisposing risk factors. CONCLUSION: This case highlights the risk of thrombotic complications after COVID-19 infection, raises some concern about their underlying mechanisms, and supports the use of effective anti-thrombotic therapy. LEARNING POINTS: COVID-19 infection is associated with frequent thrombotic events.A pro-coagulative status could be triggered by the persistent inflammatory phase of the infection despite anticoagulation.Adequate antithrombotic therapy is necessary for the prevention of acute and later thrombotic complications and needs close monitoring. äLate Pulmonary Embolism after COVID-19 Pneumonia despite Adequate Riva(epmc).pdf DeepDyve Pubget Overpricing